Brown Rudnick represented transnational pharmaceutical company Lupin on its strategic development and licensing agreement with Polish biopharmaceutical company Celon Pharma S.A.  Under the agreement, Lupin and Celon will jointly develop a fluticasone/salmeterol dry powder inhaler product which is a generic version of GlaxoSmithKline's Advair Diskus®.  For last year, GSK's Advair Diskus® reportedly had annual global sales of over USD 7 billion.  Lupin will be responsible for commercialization of the product, and Celon will supply the product to Lupin for its commercialization in the United States, Canada, Mexico, and other key markets.  Rob Funsten, Co-Chair of Brown Rudnick's Global Life Sciences Group, was the lead attorney on the transaction.